Enzyme Inhibitor Collapses Neuroblastoma Tumor Growth in Mice

Researchers have identified a specific enzyme that plays a critical role in sustaining neuroblastoma, a malignancy that often begins before birth in the developing fetus. According to a study published on April 7, 2026, in the peer-reviewed journal Brain Medicine (Genomic Press), the enzyme neuronal nitric oxide synthase (nNOS) drives the growth of this cancer through the mTOR signaling cascade.

The discovery provides a mechanistic explanation for how neuroblastoma sustains itself and suggests a potential method to interrupt this process. In laboratory tests, researchers found that treating cancer cells with a selective inhibitor known as BA-101 caused tumor growth to collapse in mice. The silencing of the nNOS gene produced significant results in inhibiting the cancer.

The Role of nNOS and Nitric Oxide

Nitric oxide serves as an ancient signaling molecule in biology, typically functioning as a quiet civil servant at physiological concentrations by dilating blood vessels and carrying messages between neurons. However, at elevated concentrations, it becomes reactive and generates nitrogen species that modify proteins through S-nitrosylation.

This modification process has been implicated in every stage of cancer progression. While very high concentrations of nitric oxide can trigger apoptosis or damage DNA, the study indicates that targeting nNOS specifically suppresses AKT–TSC–mTOR signaling, which in turn inhibits the growth of neuroblastoma.

Impact on Neuroblastoma Survival Rates

Neuroblastoma accounts for approximately 28 percent of all cancers diagnosed in infants across the United States and Europe. The disease originates when neural crest cells, which should mature into sympathetic ganglia or adrenal tissue, fail to do so and instead become malignant.

The prognosis for the disease varies significantly based on its form. Some cases are gentle and regress spontaneously. However, high-risk neuroblastoma can metastasize rapidly, and the five-year survival rate for these cases has remained at approximately 40 percent for a generation.

Experimental Methodology and Results

To test the efficacy of the nNOS inhibitor, the research team established xenograft neuroblastoma by injecting SH-SY5Y cells subcutaneously into the flanks of six-week-old NOD-SCID mice. Once palpable tumors developed, the researchers administered BA-101.

The results demonstrated that the enzyme-targeting approach could impair tumor growth and induce terminal differentiation. This suggests a viable path forward for therapies targeting the specific enzymes that keep these tumors alive.

Broader Context of Enzyme Inhibition in Neuroblastoma

The targeting of enzymes to treat neuroblastoma is a subject of ongoing research. Other studies have explored different targets, such as Enhancer of Zeste Homolog 2 (EZH2). In a study published March 9, 2021, researchers found that the EZH2 inhibitor GSK343 decreased neuroblastoma cell viability, migration, and invasion.

That specific research utilized four long-term passage neuroblastoma cell lines and two patient-derived xenolines (PDX). The administration of GSK343 in mice bearing SK-N-BE(2) neuroblastoma tumors resulted in a significant decrease in tumor growth compared to those treated with a vehicle.

While the EZH2 research focused on decreasing stemness and motility, the April 7, 2026, findings specifically highlight the nNOS-driven mTOR signaling cascade as a critical vulnerability in the survival of neuroblastoma tumors.